Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biolex Therapeutics has entered into an agreement with Merck KGaA, acting for its division for innovative pharmaceuticals Merck Serono, to evaluate antibody optimization and production in Biolex's proprietary Lex System.
Subscribe to our email newsletter
The cooperation will evaluate the ability of the Lex System to improve therapeutic profiles through optimization of antibody glycosylation structures.
Jan Turek, President and CEO of Biolex, said: “We are pleased to work with Merck Serono, a leader in biologics, to investigate the potential benefits that can be achieved by linking their novel antibody candidate with the glycosylation optimization capabilities of the Lex System.”